ATE365042T1 - Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen - Google Patents
Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungenInfo
- Publication number
- ATE365042T1 ATE365042T1 AT99903200T AT99903200T ATE365042T1 AT E365042 T1 ATE365042 T1 AT E365042T1 AT 99903200 T AT99903200 T AT 99903200T AT 99903200 T AT99903200 T AT 99903200T AT E365042 T1 ATE365042 T1 AT E365042T1
- Authority
- AT
- Austria
- Prior art keywords
- morpholinol
- sexual disorders
- treat sexual
- treat
- disorders
- Prior art date
Links
- OURXRFYZEOUCRM-UHFFFAOYSA-N 4-hydroxymorpholine Chemical compound ON1CCOCC1 OURXRFYZEOUCRM-UHFFFAOYSA-N 0.000 title 1
- 230000001568 sexual effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9801230.5A GB9801230D0 (en) | 1998-01-21 | 1998-01-21 | Pharmaceutically active morpholinol |
| US7218098P | 1998-01-22 | 1998-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE365042T1 true ATE365042T1 (de) | 2007-07-15 |
Family
ID=26312986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99903200T ATE365042T1 (de) | 1998-01-21 | 1999-01-20 | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6274579B1 (de) |
| EP (2) | EP1047428B1 (de) |
| JP (1) | JP2002501025A (de) |
| KR (1) | KR100568063B1 (de) |
| CN (2) | CN1255389C (de) |
| AP (1) | AP1229A (de) |
| AT (1) | ATE365042T1 (de) |
| AU (1) | AU755536B2 (de) |
| BR (1) | BR9907203A (de) |
| CA (1) | CA2318268A1 (de) |
| CY (1) | CY1106828T1 (de) |
| DE (1) | DE69936335T2 (de) |
| DK (1) | DK1047428T3 (de) |
| EA (1) | EA002410B1 (de) |
| EE (1) | EE04452B1 (de) |
| ES (1) | ES2288012T3 (de) |
| HR (2) | HRP20051024A2 (de) |
| HU (1) | HUP0100900A3 (de) |
| ID (1) | ID26334A (de) |
| IL (2) | IL137346A0 (de) |
| IS (1) | IS2494B (de) |
| NO (2) | NO326878B1 (de) |
| NZ (3) | NZ505809A (de) |
| PL (1) | PL193622B1 (de) |
| PT (1) | PT1047428E (de) |
| SG (1) | SG115489A1 (de) |
| SK (1) | SK10912000A3 (de) |
| TR (1) | TR200002126T2 (de) |
| WO (1) | WO1999037305A1 (de) |
| YU (1) | YU67102A (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7098206B2 (en) * | 1998-01-21 | 2006-08-29 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6998400B2 (en) * | 1998-01-22 | 2006-02-14 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| EP1051167A1 (de) | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Pharmazeutische verwendungen von optisch reinem (-)- bupropion |
| JP2002501891A (ja) * | 1998-01-29 | 2002-01-22 | セプラコア インコーポレーテッド | 光学的に純粋な（＋）−ビュープロピオンの医薬用途 |
| US6734213B2 (en) | 1999-01-20 | 2004-05-11 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6855820B2 (en) | 1999-01-20 | 2005-02-15 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| US6342496B1 (en) * | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
| WO2001026641A2 (en) * | 1999-10-13 | 2001-04-19 | Glaxo Group Limited | Morpholinol derivatives for the treatment of obesity |
| GB0003232D0 (en) * | 2000-02-11 | 2000-04-05 | Smithkline Beecham Plc | Novel composition |
| US7145649B2 (en) * | 2000-12-21 | 2006-12-05 | Brasscorp Limited | Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing |
| US6979104B2 (en) | 2001-12-31 | 2005-12-27 | R.J. Doran & Co. LTD | LED inspection lamp |
| US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
| JP4545584B2 (ja) * | 2002-05-17 | 2010-09-15 | デューク ユニバーシティ | 肥満を治療するための方法 |
| GB0219687D0 (en) * | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
| US7384941B2 (en) * | 2002-08-23 | 2008-06-10 | Eli Lilly And Company | 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors |
| RU2350327C2 (ru) * | 2003-04-29 | 2009-03-27 | Ориксиджен Серапьютикс, Инкорпорэйтд | Составы, вызывающие потерю веса |
| EP1678151A1 (de) * | 2003-10-27 | 2006-07-12 | Smithkline Beecham Corporation | Dynamisches kinetisches verfahren zur optischen trennung von diastereomeren zur herstellung von (+)-(2s, 3s)-2-(3-chlorphenyl)-3,5,5-trimethyl-2-morpholinol und salzen und solvaten davon |
| GB0325055D0 (en) * | 2003-10-27 | 2003-12-03 | Smithkline Beecham Corp | New process |
| GB0326148D0 (en) | 2003-11-10 | 2003-12-17 | Lilly Co Eli | Morpholine derivatives |
| GB0327195D0 (en) * | 2003-11-21 | 2003-12-24 | Smithkline Beecham Corp | Novel use |
| GB0327619D0 (en) * | 2003-11-27 | 2003-12-31 | Smithkline Beecham Corp | New use |
| US7429580B2 (en) | 2004-01-13 | 2008-09-30 | Orexigen Therapeutics, Inc. | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
| US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
| BRPI0510593A (pt) * | 2004-05-03 | 2007-11-20 | Univ Duke | composições para afetar a perda de peso |
| FI117283B (fi) | 2005-02-04 | 2006-08-31 | Kone Corp | Hissijärjestelmä |
| EP1951212A2 (de) | 2005-11-22 | 2008-08-06 | Orexigen Therapeutics, Inc. | Zusammensetzungen und verfahren zur erhöhung der insulinsensitivität |
| EP1968603A4 (de) * | 2006-01-03 | 2013-01-16 | Algebra Inc | Therapeutische aminarylsulfonamidkonjugatverbindungen |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| CA2668885C (en) | 2006-11-09 | 2016-08-02 | Orexigen Therapeutics, Inc. | Methods for administering weight loss medications |
| TW201811315A (zh) | 2006-11-09 | 2018-04-01 | 美商歐瑞根治療有限公司 | 層狀醫藥調配物 |
| US20090075994A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched radafaxine |
| EP2303025A4 (de) | 2008-05-30 | 2012-07-04 | Orexigen Therapeutics Inc | Verfahren zur behandlung von eingeweidefettbeschwerden |
| AU2010236404B2 (en) | 2009-04-15 | 2016-11-03 | Research Triangle Institute | Monoamine reuptake inhibitors |
| EP3659604A1 (de) | 2010-01-11 | 2020-06-03 | Nalpropion Pharmaceuticals, Inc. | Verfahren zur bereitstellung einer gewichtsverlusttherapie für patienten mit schweren depressionen |
| JP2013526583A (ja) | 2010-05-21 | 2013-06-24 | リサーチ・トライアングル・インスティチュート | フェニルモルホリンおよびその類似体 |
| WO2011146821A2 (en) | 2010-05-21 | 2011-11-24 | Research Triangle Institute | 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence |
| US9510405B2 (en) | 2011-06-30 | 2016-11-29 | Schneider Electric Industries Sas | Dual power SMPS for a modular lighting system |
| CN102670617B (zh) * | 2012-04-13 | 2013-03-20 | 湖南大学 | 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用 |
| PT3730132T (pt) | 2012-06-06 | 2022-08-16 | Nalpropion Pharmaceuticals Llc | Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular |
| CN105949142B (zh) * | 2016-05-21 | 2018-03-27 | 南华大学 | 具有抗抑郁活性的单一手性化合物及其制备方法和应用 |
| RU2763728C1 (ru) * | 2021-06-17 | 2021-12-30 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US170430A (en) * | 1875-11-30 | Improvement in furnaces for heating steel in tempering | ||
| GB8417170D0 (en) * | 1984-07-05 | 1984-08-08 | Wellcome Found | Heterocyclic pharmaceutical compounds |
| GB9108629D0 (en) | 1991-04-23 | 1991-06-12 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
-
1999
- 1999-01-20 IL IL13734699A patent/IL137346A0/xx not_active IP Right Cessation
- 1999-01-20 NZ NZ505809A patent/NZ505809A/xx unknown
- 1999-01-20 HR HR20051024A patent/HRP20051024A2/hr not_active Application Discontinuation
- 1999-01-20 JP JP2000528287A patent/JP2002501025A/ja active Pending
- 1999-01-20 SG SG200204411A patent/SG115489A1/en unknown
- 1999-01-20 DE DE69936335T patent/DE69936335T2/de not_active Expired - Lifetime
- 1999-01-20 CN CNB2004100085595A patent/CN1255389C/zh not_active Expired - Fee Related
- 1999-01-20 DK DK99903200T patent/DK1047428T3/da active
- 1999-01-20 CA CA002318268A patent/CA2318268A1/en not_active Abandoned
- 1999-01-20 EP EP99903200A patent/EP1047428B1/de not_active Expired - Lifetime
- 1999-01-20 US US09/233,531 patent/US6274579B1/en not_active Expired - Fee Related
- 1999-01-20 EA EA200000691A patent/EA002410B1/ru not_active IP Right Cessation
- 1999-01-20 AT AT99903200T patent/ATE365042T1/de active
- 1999-01-20 WO PCT/US1999/001134 patent/WO1999037305A1/en not_active Ceased
- 1999-01-20 ID IDW20001597A patent/ID26334A/id unknown
- 1999-01-20 IL IL16194299A patent/IL161942A0/xx unknown
- 1999-01-20 CN CNB998042706A patent/CN1203858C/zh not_active Expired - Fee Related
- 1999-01-20 HR HR20000494A patent/HRP20000494B1/xx not_active IP Right Cessation
- 1999-01-20 ES ES99903200T patent/ES2288012T3/es not_active Expired - Lifetime
- 1999-01-20 EP EP07110283A patent/EP1829544A1/de not_active Withdrawn
- 1999-01-20 NZ NZ529316A patent/NZ529316A/en unknown
- 1999-01-20 TR TR2000/02126T patent/TR200002126T2/xx unknown
- 1999-01-20 SK SK1091-2000A patent/SK10912000A3/sk unknown
- 1999-01-20 HU HU0100900A patent/HUP0100900A3/hu unknown
- 1999-01-20 AU AU23280/99A patent/AU755536B2/en not_active Ceased
- 1999-01-20 EE EEP200000438A patent/EE04452B1/xx not_active IP Right Cessation
- 1999-01-20 PL PL99342012A patent/PL193622B1/pl not_active IP Right Cessation
- 1999-01-20 AP APAP/P/2000/001869A patent/AP1229A/en active
- 1999-01-20 KR KR1020007007996A patent/KR100568063B1/ko not_active Expired - Fee Related
- 1999-01-20 BR BR9907203-3A patent/BR9907203A/pt not_active Application Discontinuation
- 1999-01-20 PT PT99903200T patent/PT1047428E/pt unknown
- 1999-01-20 NZ NZ520349A patent/NZ520349A/en unknown
-
2000
- 2000-07-20 NO NO20003721A patent/NO326878B1/no not_active IP Right Cessation
- 2000-07-20 IS IS5568A patent/IS2494B/is unknown
-
2001
- 2001-06-22 US US09/886,391 patent/US6391875B2/en not_active Expired - Fee Related
-
2002
- 2002-09-06 YU YU67102A patent/YU67102A/sh unknown
-
2007
- 2007-08-31 CY CY20071101117T patent/CY1106828T1/el unknown
-
2008
- 2008-08-14 NO NO20083529A patent/NO20083529L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE365042T1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
| ATE288748T1 (de) | Verwendung von retigabin zur behandlung von neuropathischen schmerzen | |
| DE69918222D1 (de) | Intranasale Zubereitungen zur Behandlung sexueller Störungen | |
| ATE247987T1 (de) | Behandlung zur beseitigung von gerüchen | |
| DE69722681D1 (de) | Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen | |
| ATE247117T1 (de) | Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen | |
| DE69922914D1 (de) | Stimulationssystem zur Behandlung von Erkrankungen bezüglich des Magenspeiseröhrenreflux | |
| DE69925306D1 (de) | Behandlung von kohlenwasserstoffgas | |
| ATE419856T1 (de) | Verwendung von rimexolon zur behandlung von augentrockenheit | |
| ATE456375T1 (de) | Verwendung von botulinum toxin zur behandlung von neuralgischen schmerzen | |
| ATE452642T1 (de) | Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen | |
| ATE353218T1 (de) | Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis | |
| DE60015516D1 (de) | Verwendung von makroliden zur behandlung von trockenen augen | |
| ATE526982T1 (de) | Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen | |
| ATE339955T1 (de) | Verwendung von escitalopram zur behandlung von generalisierten angstzuständen | |
| ATE218862T1 (de) | Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen | |
| ATE410181T1 (de) | Verwendung von intereferon gamma zur behandlung von herzhypertrophie | |
| ATE326969T1 (de) | Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation | |
| ATE270102T1 (de) | Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen | |
| DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
| ATE209891T1 (de) | Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis | |
| ATE317261T1 (de) | Verwendung von mirtazapin zur behandlung von schlafstörungen | |
| ATE190486T1 (de) | Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen | |
| DE69518438D1 (de) | Behandlung von übereregten nervenzellenfunktionen | |
| ATE267608T1 (de) | Verwendung von fsh zur behandlung von infertilität |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1047428 Country of ref document: EP |